CRNX Stock Crinetics Pharmaceuticals (CRNX, $36.64) entered a bearish trend. Expect a Downtrend continuation

GET DAILY SIGNALS

Get AI intraday signals

CRNX - Crinetics Pharmaceuticals

Bearish Trend Signal

View

Odds of DOWN Trend

Loading...

Price: $36.64

Daily change: +$1.11 (+3.12%)

Daily volume: 245.6K

Industry: Biotechnology

Momentum Indicator for CRNX turns negative, indicating new downward trend

CRNX saw its Momentum Indicator move below the 0 level on February 06, 2025. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 101 similar instances where the indicator turned negative. In of the 101 cases, the stock moved further down in the following days. The odds of a decline are at .

Technical Analysis (Indicators)

Bearish Trend Analysis

Following a 3-day decline, the stock is projected to fall further. Considering past instances where CRNX declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for CRNX entered a downward trend on February 18, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where CRNX's RSI Oscillator exited the oversold zone, of 18 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 6 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The Moving Average Convergence Divergence (MACD) for CRNX just turned positive on January 28, 2025. Looking at past instances where CRNX's MACD turned positive, the stock continued to rise in of 52 cases over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where CRNX advanced for three days, in of 278 cases, the price rose further within the following month. The odds of a continued upward trend are .

CRNX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock slightly better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. CRNX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.170) is normal, around the industry mean (12.604). P/E Ratio (0.000) is within average values for comparable stocks, (85.387). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.581). CRNX has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). CRNX's P/S Ratio (2500.000) is very high in comparison to the industry average of (252.111).

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.